Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy
In this new paper, the authors describe Immune-Modified Response Evaluation in Solid Tumors (imRECIST).
Treating solid tumors with cancer immunotherapy (CIT) can result in unconventional responses and overall survival (OS) benefits that are not adequately captured by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1.
In this new paper, published in the Journal of Clinical Oncology, the authors describe immune-modified RECIST (imRECIST) criteria, designed to better capture CIT responses: http://bit.ly/2FvqYbT
DOI: 10.1200/JCO.2017.75.1644 Journal of Clinical Oncology - published online before print January 17, 2018